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6/j.bWe evaluated a photodepletion technique to selectively deplete host-reacting T cells from human leukocyte
antigen (HLA)-matched sibling stem cell transplantations with the goal of reducing posttransplantation immu-
nosuppression to improve antimalignancy effects postallografting. Donor lymphocytes were stimulated with ir-
radiated expanded recipient T lymphocytes in an ex vivo mixed lymphocyte reaction. Alloactivated T cells
preferentially retaining the photosensitizer 4,5-dibromorhodamine 123 (TH9402)were eliminatedbyexposure
to visible light. Twenty-four patients with hematologic malignancies (16 high risk) conditioned with fludarabine,
cyclophosphamide, and totalbody irradiation received a CD34-selected stem cell allograft from an HLA-
matched sibling along with 5  106/kg selectively depleted donor T cells. Low-dose cyclosporine was used
for posttransplantation immunosuppression. Eleven patients survived at a median of 30 months. Probabilities
(6 SEM) for overall and disease-free survival are 39% 6 12% and 30% 6 12%, respectively, whereas grade
III-IV acute graft-versus-host disease (aGVHD) was 13%6 7%. Six patients relapsed, with a relapse probability
of 27%6 10%.These results suggest that selectively photodepleted allografts inmatched sibling transplantations
followed by low-dose immunosuppression may protect against severe aGVHD but is associated with delayed
immune recovery.
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A persisting limitation of allogeneic stem cell
transplantation (SCT) is the close association between
the beneficial graft-versus-leukemia (GVL) effect and
life-threatening graft-versus-host disease (GVHD),
both mediated by alloreacting donor T lymphocytes.
Transplant outcomes can be improved by preventing
GVHD by posttransplantation immunosuppression
or T cell depletion of the allograft. However, both ma-
neuvers restrict the full potential of the GVL effect to
prevent relapse of the malignancy, which remains 1 of
the major limitations to the improvement of SCT out-
come [1]. One strategy to prevent GVHD while con-
serving the GVL effect is to selectively deplete the T
lymphocytes that cause GVHD before SCT [2]. Pre-
clinical experiments demonstrate that if donor lym-
phocytes alloactivated by lymphocytes from the
patient are eliminated, myeloid leukemia-specific lym-
phocytes remain that may mediate GVL [3-5]. This1855
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by leukemia-free patient-derived antigen-presenting
cells (APCs). Alloactivated donor lymphocytes can
then be targeted for removal by antibodies to activa-
tion markers, dye-dilution, apoptosis induction, or
photodepletion (PD) [2]. Selective depletion (SD)
techniques have been evaluated in several clinical
SCT trials [6-8]. In haploidentical transplantations,
SD donor lymphocyte infusions contributed to
posttransplantation immune reconstitution with
reduced rates of infection and lowered nonrelapse
mortality (NRM).
We previously used a CD25 immunotoxin to selec-
tively deplete allografts to reduce posttransplantation
immunosuppression and enhance GVL effects [7].
With low-dose cyclosporine as posttransplantation im-
munosuppression, there was a 12% probability of grade
III-IVGVHDand relapse rates of 56% in 16 elderly pa-
tients with advanced hematologic malignancies. Acute
GVHD was associated with low donor regulatory T
cellnumbers andpoordepletionefficiency.Toavoidpo-
tential disadvantages of the CD25 activation marker as
a target for allodepletion, we chose to use a PD tech-
nique, previously validated in MHC-mismatched
donor-recipient pairs in mice and humans [9,10]. In
this approach, alloactivated donor T cells are
eliminated after light exposure based on their
preferential retention of the photosensitizer 4,5-
dibromorhodamine 123 (TH9402) (Kiadis Pharma,
The Netherlands). We established a clinical-grade,
good manufacturing practice-based PD approach that
depleted alloreactiveT cells frommixed lymphocyte re-
actions (MLRs) in mismatched andmatched pairs with-
out compromising third-party alloreactivity [11]. Here
wepresent a clinical trial in 24patientswithhematologic
malignancies receiving a myeloablative preparative reg-
imen followed by a CD34-cell selected transplant to-
gether with 5  106/kg PD donor T cells on day
0 fromanHLA identical sibling donor.Low-dose cyclo-
sporine (CSA) was used as sole GVHDprophylaxis, but
was eliminated in a stepwise fashion in successive co-
horts. Results suggest that PD can decrease acute
GVHD (aGVHD) while maintaining GVL.PATIENTS AND METHODS
Patients
Patients with hematologic malignancies, excluding
T-lymphocytic malignancies, between the ages of 17
and 75 years, and with an HLA-identical sibling donor
were eligible for this study. Between July 2007 and
October 2009, 24 patients underwent a PD SCT
from an HLA-identical sibling on the National Heart,
Lung and Blood Institute institutional review board
approved protocol (07-H-0136; clinical trials registra-
tion number NCT00467961, FDA IND #13305), anddonors provided written informed consent before en-
rolling in the transplantation protocol.
Generating Alloactivated Donor Lymphocytes
The techniques used to produce the PD product
were previously reported [11]. Briefly, recipient stimu-
lator lymphocytes were obtained by CD3-selection
(Miltenyi Biotech, Bergisch Gladbach, Germany)
from a single leukapheresis product and cultured in
X-VIVO 20 (Cambrex Bio Science, Walkersville,
MD) supplemented with 2.0% autologous heat-
inactivated plasma and 100 IU/mL interleukin-2 (Pro-
leukin; Chiron, Everyville, CA) in gas-permeable
polyolefin tissue culture bags (Lifecell PL732; Baxter
Cellular Therapies, Deerfield, IL) precoated with
OKT3 antibody (murumonab-CD3, Orthoclone
OKT3; Ortho Biotech, Horsham, PA). Cells were in-
cubated at 37C, in 7% CO2, and 90% humidity, add-
ing medium to maintain the cell concentration
between 0.5  106 and 1.5  106 cells/mL. Stimulator
cells were harvested after 10 to 12 days, concentrated,
washed, and cryopreserved in 5%DMSO. SCTdonors
underwent 8- to 12-liter leukapheresis to collect 8 to
12  109 mononuclear cells. Stimulator cells were
thawed, irradiated to 25 Gy, resuspended in X-VIVO
20 (Cambrex Bio Science) supplemented with 2.0%
autologous heat-inactivated plasma at a concentration
of 5  106 cells/mL, and combined with responder
cells at a ratio of 1:1. Responders and stimulators
were cocultured for 72 hours at 37C in 7% CO2. Co-
cultures were performed in gas-permeable polyolefin
tissue culture bags (Lifecell PL732).
PD
Cocultures were washed and resuspended at a con-
centration of 5  106 cells/mL and incubated at 37C
with 7.5 mM of 4,5-dibromorhodamine 123 (TH9402;
Kiadis Pharma, Amsterdam, The Netherlands). After
40 minutes of incubation, cells were centrifuged and
resuspended in TH9402-free medium for 90 minutes
to accelerate dye efflux, and then exposed to 5 Joule/
cm2 light (514 nm wavelength; Theralux device,
Model 514, Kiadis Pharma). Cells were cryopreserved
in 5% DMSO and 6% pentastarch, and maintained in
liquid nitrogen (2200C to 2150C), thawed, and
transfused after product release criteria ($70% viabil-
ity with CD31 $50% of viable cells, endotoxin\5
EU/mL, mycoplasma negative, and all microbiology
cultures without growth) were satisfied.
Transplant Procedure
Patients were conditioned with 125 mg/m2 of flu-
darabine (Flu; days28 to24) and 120 mg/kg of cyclo-
phosphamide (Cy; days 23 to 22), and age-adapted
fractioned totalbody irradiation (TBI) in 8 fractions
days 27 to 24 (total 12 Gy for patients #55 years
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to make the PD product, donors were mobilized
with granulocyte-colony stimulating factor (G-CSF)
for 6 days before apheresis. The stem cell collection
was depleted of T lymphocytes by CD341 positive se-
lection (Miltenyi CliniMacs System, Miltenyi Biotec
Inc., Auburn, CA). On the day of transplantation, all
patients received a fixed dose of 5  106/kg viable
PD CD31 cells, together with a CD34-selected 3-4
log T cell-depleted stem cell product (3.1-9.5  106
CD34 cells/kg) from their HLA-matched sibling.
Study Design
The trial was designed to safely evaluate the effi-
cacy of PD to prevent severe aGVHD. To mitigate
any GVHD, all patients received low-dose CSA for
GVHD prophylaxis to achieve a plasma level of 100-
200 ng/mL, starting day 24 before transplantation.
To evaluate if CSA was needed to prevent severe
GVHD after PD, we used a sequential 3-cohort CSA
deescalation design, with grade III-IV aGVHD as
the primary endpoint: In the absence of more than 3
cases of grade III-IV aGVHD per cohort, CSA could
be tapered by day 190 (cohort 1), day 145 (cohort
2), and day 13 (cohort 3). The cohort size of 17 pa-
tients was based on an expected rate of acute grade
III/IV GVHD of 12% to 41% from prior transplanta-
tion experience with low-dose CSA [7] and provided
a power of .85% (a 5 0.05).
Supportive Care
Patients received transfusion support, standard
catheter care, prophylaxis of viral infection with valacy-
clovir, fungal infection with fluconazole, and pneumo-
cystis infection with sulfamethoxazole/trimethoprim in
accordance with the Guidelines for Management in
Allogeneic Hematopoietic Stem Cells Transplant Re-
cipients published by the CDC [12].
Definitions
Acute leukemia in first complete remission (CR1),
myelodysplastic syndrome (MDS) with Intermediate-I
WorldHealthOrganization grading, and patients with
chronic myelogenous leukemia (CML) in the chronic
phase were categorized as standard risk for transplant.
More advanced disease (second complete remission
[CR2] or greater), primary refractory or relapsed dis-
ease, and secondary acute myelogenous leukemia
(AML) were categorized as high risk for transplant.
GVHD was categorized by the Glucksberg grading
system [13,14]. Overall survival was calculated from
the interval between the date of transplantation and
death, or last follow-up visit. Relapsed disease for acute
leukemia andMDS was defined by morphologic or cy-
togenetic evidence, in peripheral blood or bone mar-
row. For CML, relapsed disease was defined byhematologic, cytogenetic, or molecular evidence of re-
currence. NRM was defined as the time from trans-
plantation until death from infectious cause, graft
failure, GVHD, or any other cause unrelated to dis-
ease. Engraftment was defined as absolute neutrophil
count .500/mL for 3 consecutive days, and unsup-
ported platelet count of .20,000 or 50,000/mL for 3
consecutive days or detection of donor DNA by
PCR-short tandem repeat.
Statistical Analysis
Survival was measured to the last contact date or
death. The probability of transplant outcomes was es-
timated according to the Kaplan-Meier method, and
graphs were generated with the use of Prism 4.00 for
Windows software (GraphPad Software, San Diego,
CA). P values of .05 or less were considered significant.
Date of analysis was December 1, 2010.RESULTS
Patients and Outcome
Patient characteristics and outcome are shown in
Table 1. The median age at SCT for the 14 males
and 10 females was 43.5 years (range: 23-68). Indica-
tion for SCT included AML (n 5 9), MDS (n 5 7),
acute lymphoblastic leukemia (ALL) (n 5 4), non-
Hodgkin lymphoma (n 5 2), and CML (n 5 2), with
16 of the patients considered high risk and 8 patients
considered standard risk for relapse at the time of
SCT. All 24 patients received a PD SCTwith amedian
of 6.3  106/kg CD341 stem cells (range: 3.1-9.5 
106/kg) containing a median of 1.1 103/kg unmanip-
ulated residual CD31 cells (range: 0-7  103/kg). Me-
dian PD product viability was 90% for all products at
time of cryopreservation (range: 70%-96%), and all
PD products were infused at a predetermined dose of
5  106 viable CD31 cells/kg based on precryopreser-
vation viability and quantification. Infusions of all cell
products were well tolerated with no immediate seri-
ous adverse events.
Engraftment
Engraftment was rapid for all patients, with.95%
donor myeloid chimerism occurring by day 14, and
.95% donor T cell chimerism occurring for the ma-
jority of patients by day 30 (median 98%; range:
30%-100%). Neutrophil engraftment occurred at
a median of 12 days after SCT (range: 9-17), and on
day 30 a median absolute lymphocyte count of 761/
mL was achieved (range: 290-2486/mL). Platelet en-
graftment of .20,000/mL occurred a median of 9
days (range: 5-21), and engraftment of .50,000/mL
platelets occurred a median of 13 days (range: 9-49) af-
ter transplantation.
Table 1. Patient Outcomes
Patient Age/Sex Diagnosis Risk
Day of aGVHD Onset
(Maximum Grade II-IV)
cGVHD Day CSA Stopped Outcome Follow-up (Days)<45 <90 >90
Cohort 1 CSA tapered off at day 90
1 38 F ALL H 90 NRM *330
2 28 F ALL H 90 1233
3 43 M NHL H 90 Relapse 1191
4 53 M MDS/AML H II limited continued NRM *810
5 41 M MDS H II limited continued NRM *917
6 47 M MDS S limited 90 1073
7 28 M CML H 90 981
8 46 F AML S limited 90 953
9 38 F ALL S II limited continued NRM *443
10 44 M CML H 90 904
11 68 M MDS H 90 876
12 65 M MDS H II extensive continued NRM *292
13 68 M MDS S II limited continued Relapse *183
14 46 M AML S limited 90 806
15 30 F MDS S limited 90 NRM *414
16 59 F AML H limited 90 Relapse *218
17 29 M NHL H 90 Relapse 638
Cohort 2 CSA tapered off at day 45
18 24 M AML H IV extensive continued NRM *302
19 48 F MDS H 45 Relapse *257
20 47 F MDS/AML H limited continued 582
21 36 F AML H limited 45 554
22 23 M AML H IV limited continued NRM *266
23 44 F AML S III continued NRM *65
24 24 M ALL S II 45 Relapse *268
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; CSA, cyclosporine; ALL, acute lymphoblastic leukemia; H,
high risk; NRM, nonrelapsemortality; NHL, non-Hodgkin lymphoma; MDS, myelodysplastic syndrome; AML, acutemyelogenous leukemia; CML, chronic
myelogenous leukemia; S, standard risk.
*Died.
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Eight of the 24 patients developed aGVHD
greater than grade I before day 100 after SCT (5 grade
II, 3 grade III-IV). One patient developed aGVHD
108 days after SCT, after receiving an unmanipulated
donor lymphocyte infusion to treat decreasing donor
T cell chimerism. One patient had a recurrence of
aGVHD on day 320 after SCT when she presented
with grade IV skin GVHD occurring after an unma-
nipulated donor lymphocyte infusion given in her
home country to treat a misdiagnosed recurrence of
ALL (expansion of CD331TdT2 precursors noted
in bone marrow specimen following medication-
induced marrow aplasia). In the first cohort of 17
patients, CSA was tapered and stopped between days
90-110 in 12 patients. CSAwas continued in 5 patients
who developed grade II GVHD. No patient in this
cohort developed severe aGVHD (grade III-IV). Be-
cause the criteria for continuing to the second cohort
were met, 7 patients were entered into the second
cohort where CSA was scheduled for taper on day
45. In 3 patients, CSA was successfully tapered with-
out occurrence of severe GVHD, but 3 developed
grade III-IV acute GVHD while on CSA treatment:
1 with grade III gastrointestinal symptoms on day
36, 1 with grade III liver and grade IV skin manifesta-
tions on day 27 following an episode ofsulfamethoxazole-induced toxic epidermal necrolysis,
and 1 with grade III gastrointestinal and grade IV liver
disease on day 64 (but still receiving CSA for earlier
development of skin GVHD). Probabilities (6SEM)
of aGVHD were 38% 6 10% for grades II-IV and
13%6 7% for grades III-IV (Figure 1A). One patient
experienced a recurrence of aGVHD of the gastroin-
testinal tract occurring after day 100, and received
therapy with second-line aGVHD therapy. The 3 pa-
tients who developed grade III-IV GVHD died of in-
fectious complications.
Chronic GVHD (cGVHD)
Fourteen patients developed cGVHD: 12 limited
and 2 extensive, with a probability (6SEM) of develop-
ing cGVHD of 65% 6 11%.
Relapse
Six high-risk patients (2 MDS, 1 ALL, 1 AML in
second or subsequent remission, and 2 B cell malig-
nancies transplanted with resistant disease) relapsed
at a median of 187 days post-SCT (range: 147-349
days). Two patients with MDS (patients 13 and 19)
and 1 patient with AML (patient 16) died of relapsed
leukemic disease. The 2 patients with B cell malignan-
cies (patient 3 with mantle cell lymphoma, patient 17
with diffuse large B cell lymphoma) responded
Figure 1. (A) Probability of aGVHD; (B) probability of relapse of hematologic disease; (C) Probability of nonrelapse mortality; (D) probability of overall
survival; (E) probability of disease-free survival.
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unmanipulated donor lymphocyte infusion, and cur-
rently survive in a complete remission (Table 1). One
standard-risk patient with ALL (patient 24) relapsed
on day 202, and was lost to follow-up after returning
to his home country for palliative care 268 days after
SCT. Patient 10 experienced a molecular relapse of
CML after stopping imatinib therapy, 730 days after
SCT. This patient is now in molecular remission on
imatinib. The probability (6SEM) of hematologic re-
lapse was 29 6 13% for high-risk patients, and 27 6
10% overall (Figure 1B).
Infectious Complications
Serious adverse events requiring hospitalization
after SCT occurred frequently on this protocol and
persisted beyond the early posttransplantation period.
Patients experienced frequent viral reactivations, and
recurrent bacterial, viral, and fungal infections.
Twenty of 24 patients experienced reactivation of
CMV with a median of 2 episodes (range: 1-3) requir-
ing treatment in the first 100 days after SCT (including
2 initially CMV seronegative recipients receiving SCTfrom seropositive donors). Five patients experience
viral associated hemorrhagic cystitis (2 BK virus, 2 ad-
enovirus, 1 both), and 1 patient died of respiratory syn-
cytial virus pneumonitis (patient 1). Five patients
experienced recurrent bacterial infections, 4 of whom
died of bacterial pneumonia (patients 5, 9, 22, and 23).
Four patients developed invasive fungal infections
(1 zygomycosis, 3 aspergillus), 1 of whom died of ex-
tensive pulmonary zygomycosis (patient 15). Because
of the unexpected duration and severity of these infec-
tious complications, the trial was stopped after the
24th patient was enrolled.
NRM, Overall Survival, and Disease-Free
Survival
Patients experienced a high rate of late NRM
(Table 1 and Figure 1C), with a probability of 48%
6 15% in cohort I, 54% 6 22% in cohort II, and
53% 6 14% overall. Causes of death were: bacterial
or fungal infection (5), respiratory syncytial virus
(RSV) pneumonia (1), congestive heart failure (1),
bronchiolitis obliterans syndrome (1), and sudden
death with no identifiable etiology (1). Only 4 patients
1860 Biol Blood Marrow Transplant 17:1855-1877, 2011S. Mielke et al.had relapsed leukemia at the time of death. The prob-
ability of overall survival and DFS were 39% 6 12%
and 30% 6 12%, respectively (Figures 1D and E).DISCUSSION
An effective SD technique could provide a widely
applicable technology to deliver an SCT with maxi-
mum GVL potential and minimal aGVHD, and im-
prove outcome by reducing relapse, especially in
high-risk patients. This study demonstrates the feasi-
bility of using a PD technique to reduce T cells causing
aGVHD from the graft before SCT. The primary ob-
jective of this protocol was to determine if depletion of
alloreactive T cells before SCT by PD would avoid se-
vere aGVHD within the first 3 months of transplanta-
tion and obviate the need for posttransplantation
GVHD prophylaxis. In the first cohort, no patients
developed grade III-IV aGVHD, indicating that the
risk for severe aGVHD was low in the presence of
low-dose CSA given during the first 90 days after
SCT. However, determining whether CSA posttrans-
plantation prophylaxis could be safely reduced to 45
days was not possible because of early termination of
the trial. In the second cohort, CSA was successfully
withdrawn on day 45 in only 3 out of 7 patients as a re-
sult of GVHD developing in 4 patients requiring con-
tinued CSA administration beyond day 45. Overall, 3
of the 24 patients enrolled in this study developed
grade III-IV aGVHD before day 100, with a probabil-
ity of 13% 6 7%. Thus, although the procedure was
not completely effective, for most patients the infusion
of 5  106/kg PD T cells successfully avoided severe
aGVHD.Whether severe aGVHDwas related to vari-
ables in the PD procedure or intrinsic variations,
donor-recipient combination remains unanswered.
Perhaps helped by the rapid donor T cell engraft-
ment, the GVL effects of the transplantation appeared
to be well conserved after PD. Despite the fact that
two-thirds of the patients were at a high risk for re-
lapse, the probability of hematologic relapse was low
(27% 6 10%). Of the 6 patients who relapsed, 2 had
B cell lymphomas and were treated with chemother-
apy followed by an unmanipulated donor lymphocyte
infusion. Only 3 patients died of relapse as the primary
cause.
Although day 100 overall mortality was only 4%
and there was no severe acute GVHD in the first co-
hort, an unexpected outcome was the high rate of
late infections that often accompanied chronic or per-
sisting aGVHD, with a resultant late NRM (53%) and
median survival of only 568 days.We also encountered
unusual posttransplantation complications including 1
autoimmune hemolytic anemia, neutropenia related to
T cell large granular lymphoproliferative disorder in 2
patients, and 3 cases of chronic renal failure, 2 requir-ing dialysis. Recurrent infectious complications also
led to several prolonged hospitalizations and late read-
missionsmore than 6months after SCT. For these rea-
sons, we elected to stop the study early.
The failure of allodepletion and development of
severe aGVHD in 3 patients indicates either inability
of recipient cells to activate donor cells or a failure of
the PD process. In 3 large-scale preclinical experi-
ments with PD, we demonstrated reduction in allor-
eactivity [10], but alloreacting cells generated
between HLA-matched siblings are at the limit of de-
tection by cytotoxic and helper T lymphocyte precur-
sor (CTLp/HTLp) frequency assays, prohibiting the
use of such assay results as release criteria [15]. Fur-
thermore, it is generally acknowledged that no assay
can reliably predict GVHD after matched related
SCT. Our results are comparable to our earlier study
using a CD25 immunotoxin for allodepletion where
aGVHD and cGVHD occurred in 50% of patients
[7]. However, these results contrast with encouraging
data observed in HLA-mismatched transplants using
the PD approach [9,16] or other techniques [6-8]. It
is possible that selective T cell depletion techniques
are less able to discriminate alloreactions from
background noise in the weak alloresponses elicited
by HLA-identical siblings, compared with the very
powerful alloresponses elicited across HLA barriers.
Alternatively, the T lymphocyte recipient APC used
in our studies may have been less capable of eliciting
stronger alloresponses than PBMC [6,16] or B cell
[8] APC. Although T cell APC were chosen because
of their reproducibility and reduced risk of depleting
B cell or myeloid tissue-specific antigens (associated
leukemic antigens) [3,5], they may have been inferior
to other APCs for SD.
The high frequency of viral, bacterial, and fungal
infections persisting beyond 3 months after SCT sug-
gested that the PD process had affected graft T cell
function. We therefore studied T cell subsets in the
PD product and followed immune reconstitution in
the PD recipients. We found a reduced frequency of
central memory CD41 T cells in the PD product,
and persisting CD4 deficiency and defective immu-
nity to CMV 3 months after transplantation, which
may explain the delayed infectious complications in
our series [17].CONCLUSION
In conclusion, this clinical trial shows that PD in
the HLA-identical sibling SCT setting is effective in
achieving rapid donor reconstitution and reducing
incidence of severe aGVHD while maintaining a low
relapse rate. However, using PD may preferentially
deplete CD41 and memory T cells, resulting in a dis-
tortion of the immune repertoire and recurrent
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planned to optimize donor T cell activation and elim-
inate nonselective depletion of T cells to better adapt
the PD procedure for HLA-identical sibling SCT.ACKNOWLEDGMENTS
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